Shengqiang Li
Overview
Explore the profile of Shengqiang Li including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
215
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhu B, Ding Z, Rong X, Li S, Mei X
Pharmaceuticals (Basel)
. 2025 Jan;
18(1).
PMID: 39861153
Silymarin, an extract from milk thistle, is widely recognized for its therapeutic potential in treating liver disorders. However, its clinical utility is limited by the poor solubility and low bioavailability...
2.
Guo Q, Xu X, Li X, Mao Y, Li S, Yao Y, et al.
Front Pharmacol
. 2025 Jan;
15():1514293.
PMID: 39830355
Background: Abdominal aortic aneurysm (AAA) is one of the most dangerous types of vascular diseases worldwide. Metabolic disturbance affects disease risk and provide underlying therapeutic targets. Previous studies have reported...
3.
Chen J, Ng S, Xu P, Chen S, Li S, Chen X, et al.
Front Pharmacol
. 2024 Nov;
15:1505231.
PMID: 39605913
Introduction: The XuLing JianGu recipe (XLJGR) is an empirical traditional Chinese medicine formula used for the treatment of osteoporosis. This study aims to explore the effects of XLJGR on the...
4.
Li S, Wang Y, Lv Z, Wang Q, Jia T, Zhai Z, et al.
Int Immunopharmacol
. 2024 Sep;
142(Pt B):113177.
PMID: 39298820
Background: Angiotensin 1-7 (Ang1-7) is the classical end product of angiotensin II, which has the effects of dilating blood vessels, protecting endothelial cells, anti-hypertension, improving cardiac function, and inhibiting atherosclerosis....
5.
Zou Y, Wu S, Xu X, Tan X, Yang S, Chen T, et al.
Int Immunopharmacol
. 2024 Apr;
133:112075.
PMID: 38663316
Cuproptosis has recently been identified as a novel regulatory mechanism of cell death. It is characterized by the accumulation of copper in mitochondria and its binding to acylated proteins. These...
6.
Huang Y, Pu X, Qian H, Chuang C, Dong S, Wu J, et al.
Anal Bioanal Chem
. 2024 Jan;
416(6):1469-1483.
PMID: 38236393
This paper describes the simple and label-free detection of thrombin using optical fiber surface plasmon resonance (SPR) sensors based on gold films prepared by the cost-effective method of electroless plating....
7.
Xie L, Feng E, Li S, Chai H, Chen J, Li L, et al.
Medicine (Baltimore)
. 2023 Jun;
102(20):e33829.
PMID: 37335694
Osteoporosis (OP) is one of the major public health problems in the world. However, the biomarkers between the peripheral blood mononuclear cells (PBMs) and bone tissue for prognosis of OP...
8.
Wang D, Tian Z, Zhang P, Zhen L, Meng Q, Sun B, et al.
Biomed Pharmacother
. 2023 May;
163:114830.
PMID: 37150036
Recently, cuproptosis has been demonstrated to be a new non-apototic cell death mode that is characterized by copper dependence and the regulation of mitochondrial respiration. Cuproptosis is distinct from known...
9.
Zhang H, Zhao M, Hu S, Ma K, Li J, Zhao J, et al.
Pathogens
. 2023 Feb;
12(2).
PMID: 36839498
is a zoonotic proto-microbe that is widespread throughout the world, causes self-limiting diseases in humans or animals and even leads to sepsis and death in patients with severe cases. In...
10.
Lin R, Xie B, Xie L, Ge J, Li S
BMC Complement Med Ther
. 2022 Dec;
22(1):333.
PMID: 36522793
Background: Gushukang (GSK) capsules are a Chinese patented medicine that is widely used in clinics for the treatment of osteoporosis (OP). Animal experiments have revealed that the bone mineral density...